Curative by Design™

The Curative Design Of Verik Therapies Begins
With A "Biology First" Approach

Algorithm-guided research on molecular phenotypes has uncovered nexuses of regeneration to discover targetable changes with high curative potential.

An ideal target for solid tumors is a protein that is pivotal to the perpetuation of cancer and only found in cancer.


So how do we mine for these valuable protein gems: by digging deep into the connections between the biology of regeneration and cancer with the help of our SeleCTR process and algorithm.

Molecular phenotypes

We delve into the biology of cells and tissues undergoing development or renewal in search of regenerative nexuses.

A regenerative nexus

A regenerative nexus represents a core aspect of tissue regeneration. Nexuses must work in concert to maintain a capacity for regeneration, and, in the case of cancer, its ability to persist and return.

 A targetable change

A cancer-specific protein change that governs a nexus, creates a High Curative Potential (HCP) Target.


The nature of an HCP Protein Target means it is likely to be retained as the cancer advances and is also likely to be shared between cancer patients. This creates the possibility of serving a broad population of  patients with a reliably potent T cell therapy.


Independent clinical studies have reported the retention of shared HCP target gene expression in patients with metastatic disease.

Learn how we'll get from targets to therapies.



© 2018 Verik Bio, Inc
website design by Alice Sargent